S Lu, L Wu, H Jian, Y Cheng, Q Wang… - The Lancet …, 2023 - thelancet.com
Background In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …